NASDAQ:TNYA Tenaya Therapeutics - TNYA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.71 -0.09 (-3.21%) (As of 03/22/2023 03:25 PM ET) Add Compare Share Share Today's Range$2.67▼$2.8350-Day Range$2.10▼$3.5952-Week Range$1.64▼$14.43Volume112,462 shsAverage Volume383,465 shsMarket Capitalization$181.19 millionP/E RatioN/ADividend YieldN/APrice Target$18.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tenaya Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside593.4% Upside$19.00 Price TargetShort InterestHealthy2.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$4.56 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.43) to ($2.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector124th out of 983 stocksBiological Products, Except Diagnostic Industry20th out of 163 stocks 3.5 Analyst's Opinion Consensus RatingTenaya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Tenaya Therapeutics has a forecasted upside of 593.4% from its current price of $2.74.Amount of Analyst CoverageTenaya Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.06% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenaya Therapeutics has recently decreased by 10.27%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TNYA. Previous Next 2.1 News and Social Media Coverage News SentimentTenaya Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tenaya Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 31 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,557,070.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders34.24% of the stock of Tenaya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tenaya Therapeutics are expected to decrease in the coming year, from ($2.43) to ($2.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tenaya Therapeutics (NASDAQ:TNYA) StockTenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.Read More Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNYA Stock News HeadlinesMarch 20, 2023 | americanbankingnews.comTenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $19.00 Average Price Target from AnalystsMarch 14, 2023 | americanbankingnews.comHC Wainwright Comments on Tenaya Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:TNYA)March 22, 2023 | Investing Daily (Ad)This Trade Strategy Outpaces Almost AnythingDespite the volatility of the last few years, this reclusive millionaire hasn’t closed a losing trade since July 2016. He just plugs away, executing what may be the most effective investment strategy on Earth. He turned $50K into $5.3M! Want to see the details? Click HERE to watch it for yourself. March 12, 2023 | americanbankingnews.comTenaya Therapeutics (NASDAQ:TNYA) PT Lowered to $18.00March 9, 2023 | markets.businessinsider.comLifeSci Capital Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)March 9, 2023 | finanznachrichten.deTenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 8, 2023 | finance.yahoo.comTenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 4, 2023 | seekingalpha.comTNYA Tenaya Therapeutics, Inc.March 22, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.January 26, 2023 | msn.comTenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You Should KnowJanuary 25, 2023 | marketwatch.comNew Report on Epilepsy Therapeutics Market: 2023 Complete Research on Prominent Player, Business Prospect, and Growth Rate By 2027January 11, 2023 | seekingalpha.comThe Take On Tenaya TherapeuticsJanuary 9, 2023 | finance.yahoo.comTenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 MilestonesDecember 21, 2022 | finance.yahoo.comInsiders who placed huge bets on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) earlier this year would be disappointed with the 23% dropDecember 7, 2022 | finance.yahoo.comTenaya Therapeutics Appoints Amy Burroughs to Board of DirectorsNovember 28, 2022 | finance.yahoo.comTenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular CardiomyopathyNovember 24, 2022 | benzinga.comMassive Insider Trade At Tenaya TherapeuticsNovember 24, 2022 | finance.yahoo.comHere's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash WiselyNovember 23, 2022 | technews.tmcnet.comTenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare ConferenceNovember 23, 2022 | finance.yahoo.comTenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare ConferenceNovember 22, 2022 | finanznachrichten.deTenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Closing of Public OfferingNovember 21, 2022 | finance.yahoo.comTenaya Therapeutics Announces Closing of Public OfferingNovember 17, 2022 | finanznachrichten.deTenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Proposed Public OfferingNovember 17, 2022 | markets.businessinsider.comTenaya Therapeutics Prices Public Offering Of 22.61 Mln Shares At $2.60/shrNovember 17, 2022 | finance.yahoo.comTenaya Therapeutics Announces Pricing of Public OfferingNovember 16, 2022 | finance.yahoo.comTenaya Therapeutics Announces Proposed Public OfferingNovember 10, 2022 | technews.tmcnet.comTenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNYA Company Calendar Last Earnings11/10/2021Today3/22/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNYA CUSIPN/A CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees106Year FoundedN/APrice Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$24.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+554.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,670,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-54.20% Return on Assets-47.44% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.64 per share Price / Book0.77Miscellaneous Outstanding Shares66,860,000Free Float43,970,000Market Cap$187.21 million OptionableNot Optionable Beta2.28 Key ExecutivesMr. Faraz Ali M.B.A. (Age 49)CEO, Sec. & Director Comp: $710.77kDr. Deepak Srivastava M.D. (Age 55)Scientific Founder, Chairman of Scientific Advisory Board & Director Comp: $18.15kMs. Leone D. Patterson M.B.A. (Age 59)Chief Financial & Bus. Officer Comp: $448.55kDr. Whittemore G. Tingley M.D. (Age 54)PH.D., Chief Medical Officer Comp: $551.18kDr. Eric N. Olson Ph.D.Scientific Founder & Member of Scientific Advisory BoardDr. Bruce R. ConklinScientific FounderDr. Saptarsi Haldar M.D.Scientific FounderDr. Sheng DingScientific FounderDr. Benoit G. Bruneau Ph.D.Scientific FounderDr. Kee-Hong Kim Ph.D. (Age 56)Chief Technology Officer More ExecutivesKey CompetitorsCEL-SCINYSE:CVMGamida CellNASDAQ:GMDAAthira PharmaNASDAQ:ATHACellectisNASDAQ:CLLSProtalix BioTherapeuticsNYSE:PLXView All CompetitorsInsiders & InstitutionsGroup Gp Lp Column IIIBought 6,779 shares on 3/10/2023Total: $17,625.40 ($2.60/share)Millennium Management LLCBought 15,168 shares on 2/15/2023Ownership: 0.271%Jasper Ridge Partners L.P.Bought 13,573 shares on 2/15/2023Ownership: 0.152%Squarepoint Ops LLCBought 61,167 shares on 2/15/2023Ownership: 0.148%Morgan StanleyBought 13,601 shares on 2/15/2023Ownership: 0.067%View All Insider TransactionsView All Institutional Transactions TNYA Stock - Frequently Asked Questions Should I buy or sell Tenaya Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tenaya Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TNYA shares. View TNYA analyst ratings or view top-rated stocks. What is Tenaya Therapeutics' stock price forecast for 2023? 6 equities research analysts have issued 1 year price objectives for Tenaya Therapeutics' shares. Their TNYA share price forecasts range from $13.00 to $24.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 578.6% from the stock's current price. View analysts price targets for TNYA or view top-rated stocks among Wall Street analysts. How have TNYA shares performed in 2023? Tenaya Therapeutics' stock was trading at $2.01 on January 1st, 2023. Since then, TNYA stock has increased by 39.3% and is now trading at $2.80. View the best growth stocks for 2023 here. When is Tenaya Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our TNYA earnings forecast. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.20. What ETFs hold Tenaya Therapeutics' stock? ETFs with the largest weight of Tenaya Therapeutics (NASDAQ:TNYA) stock in their portfolio include BlackRock Future Health ETF (BMED).Fidelity Growth Opportunities ETF (FGRO). When did Tenaya Therapeutics IPO? (TNYA) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. What is Tenaya Therapeutics' stock symbol? Tenaya Therapeutics trades on the NASDAQ under the ticker symbol "TNYA." Who are Tenaya Therapeutics' major shareholders? Tenaya Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (14.66%), Price T Rowe Associates Inc. MD (10.81%), Alyeska Investment Group L.P. (2.50%), Geode Capital Management LLC (1.15%), Trustees of Columbia University in the City of New York (0.71%) and Renaissance Technologies LLC (0.51%). Insiders that own company stock include David V Goeddel, Deepak Srivastava, Eli Casdin, Group Gp Lp Column III and Timothy Hoey. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tenaya Therapeutics' stock price today? One share of TNYA stock can currently be purchased for approximately $2.80. How much money does Tenaya Therapeutics make? Tenaya Therapeutics (NASDAQ:TNYA) has a market capitalization of $187.21 million. The company earns $-123,670,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. How many employees does Tenaya Therapeutics have? The company employs 106 workers across the globe. How can I contact Tenaya Therapeutics? The official website for the company is www.tenayatherapeutics.com. The company can be reached via phone at 650-825-6990 or via email at investors@tenayathera.com. This page (NASDAQ:TNYA) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.